Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, T-Cell

Explore clinical trials studying Lymphoma, T-Cell. Study availability and eligibility vary by location and protocol.

181 public trials 52 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, T-Cell trial results

Completed

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

NCT01871675

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +22 more
Locations
  • The Colorado Blood Cancer Institute Denver, Colorado, United States
  • Florida Cancer Specialists Sarasota, Florida, United States
  • Oklahoma University Oklahoma City, Oklahoma, United States
  • Tennessee Oncology, PLLC Nashville, Tennessee, United States
View Trial Details
Completed

A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma

NCT00322985

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Tom Baker Cancer Centre Calgary, Alberta, Canada
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • Cancer Care Manitoba Winnipeg, Manitoba, Canada
  • Queen Elizabeth II, Health Services Centre Halifax, Nova Scotia, Canada
View Trial Details
Completed

Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

NCT01466881

Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, +23 more
Locations
  • Providence Hospital Mobile, Alabama, United States
  • The University of Arizona Cancer Center-Orange Grove Campus Tucson, Arizona, United States
  • The University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
  • The University of Arizona Medical Center-University Campus Tucson, Arizona, United States
View all 161 locations
View Trial Details
Completed

Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

NCT01403415

Conditions
Childhood B Acute Lymphoblastic Leukemia, Childhood T Acute Lymphoblastic Leukemia, Hematologic Diseases, +16 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
  • Childrens Hospital of Orange County Orange, California, United States
  • Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States
View all 31 locations
View Trial Details
Completed

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

NCT00413075

Conditions
Adenoma, Adenosarcoma, Adnexal Diseases, +89 more
Locations
  • Yale New Haven Hospital New Haven, Connecticut, United States
  • Columbia University - Herbert Irving Cancer Center New York, United States
  • New York University Cancer Institute New York, United States
  • M.D. Anderson Cancer Center Houston, Texas, United States
View Trial Details
Completed

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

NCT00608361

Conditions
Adenocarcinoma, Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia, +144 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles County-USC Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
View all 23 locations
View Trial Details
Completed

RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas

NCT01198665

Conditions
Anaplastic Large Cell Lymphoma, ALK-negative, Angioimmunoblastic T Cell Lymphoma, Cutaneous T Cell Lymphoma, +15 more
Locations
  • National Cancer Center Goyang-si, Kyoungki-do, South Korea
  • Samsung Medical Center Seoul, South Korea
  • Asan Medical Center Seoul, South Korea
  • Korea Cancer Center Hospital Seoul, South Korea
View Trial Details
Completed

Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

NCT00901147

Conditions
Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative), Angioimmunoblastic T-cell Lymphoma, Enteropathy- Type T-cell Lymphoma, +20 more
Locations
  • Hospital Universiti Kebangsaan Malaysia ( HUKM ) Kuala Lumpur, Malaysia
  • Subang Jaya Medical Centre Subang Jaya, Selangor, Malaysia
  • National Cancer Center Singapore
  • Singapore General Hospital Singapore
View Trial Details

Related conditions